Is the healthcare stock in big trouble and headed for a greater decline, or are investors perhaps a bit too bearish on the ...

It has been about a month since the last earnings report for Pfizer (PFE). Shares have lost about 9.4% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading ...

We recently published a list of 8 Most Undervalued Pot Stocks to Buy According to Analysts. In this article, we are going to ...

Once a controversial European depression treatment that never made it to the U.S. | The treatment, which was once a Pfizer ...

Stocks knocked down in the first ten months of the year often suffer further damage as people sell for tax losses. But they ...

Pfizer, despite pressure from investors to look outside, elevates its cancer chief Chris Boshoff to lead overall R&D.

Pfizer's high initial dividend yield, solid ratings, and promising pipeline make it a potentially undervalued investment. See ...

On Tuesday, Pfizer Inc (PFE) stock saw a decline, ending the day at $25.77 which represents a decrease of $-0.40 or -1.53% from the prior close of $26.17. The stock opened at $26.16 and touched a low ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Company veteran Chris Boshoff, who has led Pfizer’s cancer research and marketing for more than a year, will become chief ...

On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...

The pharma leader is betting that streamlined services may be a shot in the arm for Americans seeking care with its ...